Treatment of circadian rhythm disorders
US-9060995-B2 · Jun 23, 2015 · US
Treatment of circadian rhythm disorders
US9539234B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9539234-B2 |
| Application number | US-201514688301-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 16, 2015 |
| Priority date | Jan 26, 2012 |
| Publication date | Jan 10, 2017 |
| Grant date | Jan 10, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a patient for a circadian rhythm disorder wherein the patient is being treated with a strong CYP1A2 inhibitor selected from a group consisting of fluvoxamine, ciprofloxacin, and verapamil, the method comprising: discontinuing the treatment with the strong CYP1A2 inhibitor; and then treating the patient with tasimelteion, thereby avoiding the use of tasimelteon in combination with the strong CYP1A2 inhibitor. 2. The method of claim 1 , wherein the CYP1A2 inhibitor is fluvoxamine. 3. The method of claim 1 , that comprises treating the patient for Non-24-Hour Sleep-Wake Disorder wherein the patient is light perception impaired (LPI). 4. The method of claim 3 , wherein the tasimelteon is administered at 0.5 to 1.5 hours before the target sleep time. 5. The method of claim 1 , wherein the exposure to tasimelteon in a patient being treated with tasimelteon for a circadian rhythm disorder or for a sleep disorder is reduced by avoiding use of tasimelteon in combination with fluvoxamine.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9539234B2 cover?
- Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
- Who is the assignee on this patent?
- Vanda Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification G16H50/20. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).